Connect with us

Politics & policy

Germany’s approach towards cannabis is a lesson for Europe

In this article, Adrian Clarke, chief commercial officer and co-founder of Tenacious Labs, discusses the need for Europe to develop an aligned cannabis industry.



Germany’s approach towards cannabis is a lesson for Europe

In November, Germany’s incoming coalition government announced its intention to legalise the sale of cannabis nationwide. 

“The legalisation of cannabis, long blocked by the Union, allows us to have a regulated and taxed dispensary, controllable quality and effective youth protection through education,” wrote Lars F. Lindemann, a regional cadre of the Free Democrats.

If the legislation becomes law, it would be colossal, not only because Germany would become the first major European country to legalise the substance but also it would open up a market double the size of Canada, which is already worth $3.25bn in 2021[1]. Though there are likely to be sceptics, the benefits of legalisation will be deeply and widely felt.

Whilst the country is liberalising its stance on cannabis, its approach towards alcohol is very different. Besides the broader drug harm reduction services, the coalition is planning to tighten up advertising of alcohol. There may be several reasons for this – from improving public health to reducing crime rates – but interestingly, this shift away from alcohol and towards cannabis is also felt on a consumer level too.

Over the past decade or so, the amount of alcohol consumed per capita in Germany fell from approximately 140 litres to 124 litres in 2020[2]. The Covid-19 pandemic further accelerated this trend, with per capita consumption of beer, sparkling wine and spirits decreasing 5.4 per cent, 2.1 per cent and 0.9 per cent[3].

Meanwhile, the fledgling cannabis market is only getting stronger and stronger — particularly in Europe where it is expected to be worth as much as €32bn by 2027[4]. As one of the more prominent markets, Germany alone is expected to generate as much as €16.2bn by the same year.

Germany’s announcement comes amid a global shift toward local and nationwide decriminalisation, and in some cases legalisation of cannabis. In October, for example, Luxembourg approved legislation to legalise the home cultivation and consumption of the drug.

In the UK, we are already beginning to see the start of an emerging and flourishing CBD industry. In Jersey, for example, the government is working hard to create an environment that makes it easy and safe for cannabis industry players to operate. 

The Cannabis Services Advisory Board, of which Tenacious Labs sits as chair, has been established to promote best industry practices around product development and point of sale. Not only does this create opportunities for the broader industry, but also for Jersey too. 

For a population of only 100,000, the impact of a strong cannabis industry would be significant, with one Jersey government official estimating that the initial tax income from CBD products alone could be £30m per year in the future.

However, whilst this is encouraging, the UK and the rest of Europe still lag behind Germany’s ambitions to legalise. Respective national governments would do well to learn from their ambitious German counterparts, and carefully consider legislation in their own jurisdiction that that ensures there is strong regulation in place to safeguard all stakeholders. This will open a significant market for legal cannabis growers and dealers, ushering in jobs and creating a degree of economic prosperity.

The global cannabis industry is fast-growing, and the pandemic has done much to further fuel its growth, with consumers flocking to cannabis and CBD products for a wide range of reasons – from treating physical pain to assisting sleep and improving wellbeing. This has inspired a new wave of consumers to try — and stick by — cannabis, while seemingly veering away from mass-market alcohol.

As this trend continues, it’s important that regulators and legislators in the UK sit up and take note of developments in Germany. Cannabis consumption is not going away. Instead, like in Germany, key decision-makers should look to create a market that genuinely protects consumers by offering safer, regulated products; that generates taxes for wider societal benefits; and for business, who can navigate a proper, grown-up industry.

If the rest of Europe can align the interests of all its currently disparate stakeholders by creating a similar framework, the potential for growth is limitless. Without that, the cannabis industry’s market potential will go up in smoke.

Adrian Clarke
Chief commercial officer and co-founder
Tenacious Labs





Politics & policy

Cross-party group established for recreational cannabis in Europe

#LegaliseitEP is focusing on human rights-based cannabis policy – “it is a matter of freedom”.



Cross-party group established for recreational cannabis in Europe
Home » News » Politics & policy » Germany’s approach towards cannabis is a lesson for Europe

The group, made up of MEPs from five different parties, has formed to facilitate discussions around amending policy for the personal use of cannabis in Europe.

As countries such as Malta, Germany and Luxembourg have announced progressive amendments to cannabis policy, the informal interest group is supporting human rights-based policies for the personal use of cannabis.

The group is made up of the MEPs Luke Flanagan of Ireland, The Left; Mikuláš Peksa of the Czech Republic, Greens; Monica Semedo of Luxembourg, Renew; Cyrus Engerer of Malta, S&D; and, Dorian Rookmaker of The Netherlands, ECR.

Read more: Malta officially legalises cannabis in historic first for Europe

In an open letter to 705 members of the European Parliament, the group states that Member States should have the autonomy to create cannabis policy that reflects the needs and specificities of their society. 

As well as encouraging the MEPs to join the group, the open letter also calls for more information sharing between Member States regarding recreational cannabis and for fact-based discussion on cannabis, which the group says has been subject to misinformation for a long time.

The letter states: “Due to outdated and unpredictable patchwork of legislation, citizens across the EU are often finding themselves being forced to turn to the black market or even worse, imprisoned for being in possession of small amounts of cannabis for personal use. This does not reflect the level of freedom we have come to expect from living in Europe.

“We cannot deny that with new legislation coming forward within EU Member States, we are likely to find ourselves facing repercussions at an EU level. As MEPs, we want to build on this momentum and create a cross-party interest group within the European Parliament, where we will share best practices, talk to experts, organise hearings and conferences, as well as debate the situation of personal use of cannabis within the Union.”

Monica Semendo, of Luxembourg’s Renew, stated: “I am in favour of the legalisation of cannabis and cannabis products because it is a matter of freedom. 

“It’s a matter of one’s own choice. And if someone decides to consume cannabis, they should have access to a safe product. 

“We have to focus on transparent information, education programmes and risk reduction, especially for young adults.”

Cyrus Engerer of Malta’s S&D, stated: “People should have the right to take autonomous informed decisions about their lives, including whether or not they use cannabis. 

“Let’s talk basics. No one should go to jail over a joint. And now for some real talk – many people still are. 

“Where I come from – Malta – we are the first European country to fully legalise cannabis use Germany, and Luxembourg will soon follow it. It’s time that we talk about cannabis and our personal freedoms and rights.”

Continue Reading

Politics & policy

Greenrise welcomes cannabis policy developments in Germany

The company is preparing for the potential legalisation of adult-use cannabis in Germany.



Greenrise welcomes cannabis policy developments in Germany
Home » News » Politics & policy » Germany’s approach towards cannabis is a lesson for Europe

Greenrise Global Brands has welcomed recent developments in Germany as it awaits guidelines from the German Government in the coming months.

Germany’s “traffic light” coalition made plans to legalise recreational cannabis official in November 2021 with the publication of its agreement. 

The coalition, which includes the Social Democratic Party of Germany (SPD), the Free Democratic Party (FDP) and The Greens, agreed to legalise the controlled distribution of cannabis to adults for “pleasure purposes”. With a focus on health-oriented cannabis policy, the development aims to move consumers away from the black market, control quality of products and ensure the protection of minors.

This year, five hearings are planned throughout to discuss the legislative process on the controlled supply of cannabis to adults for recreational purposes, with the first meeting being held in June, at the Federal Ministry of Health.

The Federal Government is anticipated to submit a draft law to Parliament (Bundestag) by the end of 2022.

Read more: Germany to begins consultations for cannabis legalisation

Greenrise Global, which has a wholly-owned medical cannabis subsidiary, AMP Alternative Medical Products GmbH that imports EU-GMP medical cannabis from within the European Union and elsewhere and has well-established relationships with pharmacies and clinics across Germany, has welcomed the development.

Supporter of the health benefits of cannabis and a keystone shareholder and director of Greenrise, as well as co-founder of CannaCare Health, Frank Otto, commented: “The consultation process shows that Germany is no longer talking about whether to legalise adult-use, but how. 

“We also believe that there will be a domino effect as European countries are watching very closely as Europe’s largest economy joins Canada and California in legalising cannabis for adult use.”

AMP Alternative Medical Products has reported that preliminary unaudited sales for first half year 2022 increased 14 per cent to €268,479 compared to sales of €236,399 during the first half year of 2021.

Greenrise acquired 51 per cent of CannaCare, which sells CBD wellness products through traditional retail channels in Germany and German-speaking markets in Europe, at the beginning of Q2. The company has reported that preliminary Q2 unaudited sales for CannaCare increased 187 per cent to €474,000 compared to Q1 2022 sales of €165,000.

Managing director of AMP and director of Greenrise, Dr Stefan Feuerstein, said: “The exceptional sales growth from CannaCare during the second quarter confirms our strategy of investing in CBD in addition to medical cannabis as we prepare for the potential legalisation of adult-use in Germany. 

“We look forward to the government providing guidelines in the coming months, which will provide certainty on how and when to position our businesses. 

“We expect pharmacies to play a significant role and are preparing our pharmacy customers for the possibility of selling adult-use products as well as soon as legislation is in effect. We also realigned our medical cannabis business by streamlining our medical sales team, offering more pharmaceutical cannabis products to doctors to prescribe and are preparing to import high-THC flowers from several European cultivators.”

CFO of CannaCare, Dr Tilman Spangenberg, commented: “Greenrise’s investment allowed CannaCare to launch its CBD products in three leading German drugstore chains, which dramatically increased sales in a very short period of time. 

“We expect the full impact of this sales channel to unfold in the third as well as fourth quarter. Our priorities for the remainder of this year are to grow CannaCare’s sales and operating cash flow positive by introducing new sales channels and adding additional drugstore chains.”

Continue Reading

Politics & policy

Switzerland’s amendment on medical cannabis comes into force

The Swiss government announced in June that rules for medical cannabis will be simplified.



Switzerland’s amendment on medical cannabis comes into force
Home » News » Politics & policy » Germany’s approach towards cannabis is a lesson for Europe

Today, 1 August 2022, Switzerland’s amendments to its Narcotics Act come into force, which will allow patients in the country easier access to medical cannabis.

Switzerland has now joined a number of countries across Europe that are enabling patient access to cannabis by removing its ban on the medicine. 

Previously, Switzerland’s Federal Office of Public Health (FOPH) required exceptional approval for use of medical cannabis. This reduced patient access to cannabis as administrative processing was unable to keep up with the demand from potential patients.

Read more: Switzerland approves pilot for regulated cannabis sales

The use of medical cannabis will now be subject to regular control measures. The defined limit of at least 1.0% total THC content remains unchanged. 

Under the new amendments, medical prescriptions will no longer require an exceptional permit from the FOPH. Cannabis will be reallocated from Switzerland’s Narcotics List Ordinance list from List d, which is prohibited narcotics, to List a, which is all substances subject to control measures), along with preparations such as extracts, resins, oils and tinctures. 

Read more: Cannabis regulation changes across Switzerland and Luxembourg

Dronabinol and THC will now also be included List a “provided there is an intended medical purpose”.

The new amendment enables doctors to make the decision on whether a patient requires a medical cannabis prescription, speeding up the process of accessing the medicine for patients.  

The medicine will now enter Switzerland’s pharmaceutical system and controlled by the health authority SwissMedic, which will be taking over the role of the country’s Cannabis Agency for the cultivation of medical cannabis.

Under the amendments, there will be a two-stage authorisation procedure, which will require an establishment licence and an individual licence for the cultivation of medical cannabis. 

SwissMedic has stated that the handling of cannabis for non-medical purposes continues to be generally prohibited and will continue to require an exemption from the FOPH. 

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts